Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 EV-to-EBIT is 39.36 as of Sep. 01, 2026, which is 1% below its 10-year median of 39.81. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 107 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks worse than 73.83% on this metric.
The historical rank and industry rank for WuXi XDC Cayman's EV-to-EBIT or its related term are showing as below:
STU:L74'
s EV-to-EBIT Range Over the Past 10 Years
Min: 24.63 Med: 39.81 Max: 174.06
Current: 39.44
During the past 6 years, the highest EV-to-EBIT of WuXi XDC Cayman was 174.06. The lowest was 24.63. And the median was 39.81.
STU:L74's EV-to-EBIT is ranked worse than 73.83% of 107
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.19
vs STU:L74: 39.44
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
WuXi XDC Cayman's Enterprise Value for the quarter that ended in Dec. 2025 was €7,548.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €231.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman EV-to-EBIT Related Terms
WuXi XDC Cayman EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, WuXi XDC Cayman's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's EV-to-EBIT falls into.
WuXi XDC Cayman's current Enterprise Value is €9,119.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €231.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (STU:L74) has a EV-to-EBIT of 39.36 as of Sep. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 39.81. Over the past decade, WuXi XDC Cayman's EV-to-EBIT has ranged from 24.63 to 174.06. According to the industry distribution chart, WuXi XDC Cayman ranks #79 out of 107 companies in the Medical Diagnostics & Research industry, placing it in the top 73.8%.
Is WuXi XDC Cayman's EV-to-EBIT too high?
WuXi XDC Cayman's current EV-to-EBIT of 39.36 is near median its 10-year median of 39.81. Over the past 10 years, this metric has ranged from a low of 24.63 to a high of 174.06. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.19. WuXi XDC Cayman's value of 39.36 is 62.7% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #79 out of 107 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #79 out of 107 companies for EV-to-EBIT. This places WuXi XDC Cayman in the lower half of its industry. The industry median EV-to-EBIT is 24.19. WuXi XDC Cayman's value of 39.36 is 62.7% above this benchmark. Historically, WuXi XDC Cayman's own EV-to-EBIT has ranged from 24.63 to 174.06 over the past decade. While the company's 10-year median is 39.81 vs. the industry median of 24.19, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.19, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current EV-to-EBIT of 39.36 is 62.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current EV-to-EBIT is 39.36, which is near median its own 10-year median of 39.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current EV-to-EBIT of 39.36. The current EV-to-EBIT is 39.36, which is near median its 10-year median of 39.81 and 62.7% above the Medical Diagnostics & Research industry median of 24.19. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current EV-to-EBIT is 39.36 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
